Merck Company maintains a Beta (Market Risk) of 0.1956, indicating relatively insignificant fluctuations compared to the market. As market returns increase, Merck's returns are projected to grow less than the market. Conversely, during a bear market, the potential loss from holding Merck is expected to be less severe. Merck Company anticipates a return of -0.15%. It is crucial to verify Merck Company's market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to determine if Merck Company's past performance will recur at some point in the near future. Please refer to the Merck Company dashboard, Merck Market Risk Adjusted Performance, Merck Information Ratio, and the comparison between Merck Information Ratio and Skewness for more details.
Advanced assessment of Merck
Investing in Merck & Co., Inc. (NYSE: MRK), a leading pharmaceutical company, could be a savvy move for those looking to diversify their portfolios. Despite the company's total risk alpha of
-0.29, which indicates a potential loss, the firm's potential upside of
1.63 suggests that there could be substantial growth on the horizon. Moreover, the company's high price of
$108.14 indicates a strong market performance and a robust demand for its shares. Merck's mean deviation of 0.94 also suggests a relatively low level of volatility, providing some degree of security for risk-averse investors. The company's robust trading volume, with a whopping
10.9 million shares changing hands today, demonstrates the high level of investor interest in this pharmaceutical giant. While the company's risk-adjusted performance of -0.06 may be a cause for concern, the potential for high returns may well outweigh the risks for some investors. In conclusion, while Merck's stock does carry some risks, its strong market performance and potential for growth make it a compelling option for those looking to expand their portfolios. With its high trading volume and potential upside, Merck is certainly a stock to watch in the coming months.
The successful prediction of Merck
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Merck Company, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Merck based on Merck hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Merck's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Merck's related companies.
Use Technical Analysis to project Merck expected Price
Merck technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Merck technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Merck trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Merck Gross Profit
Merck Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Merck previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Merck Gross Profit growth over the last 10 years. Please check Merck's
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
The company reported the last year's revenue of 59.28
B. Total Income to common stockholders was 14.53
B with profit before taxes, overhead, and interest of 42.08
B.
Cost of Revenue Breakdown
Merck Cost of Revenue yearly trend continues to be quite stable with very little volatility. The value of Cost of Revenue is projected to decrease to about 15.4
B. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. Merck Cost of Revenue is quite stable at the moment as compared to the past year. The company's current value of Cost of Revenue is estimated at 15.37 Billion
| 2016 | 14.03 Billion |
| 2017 | 12.91 Billion |
| 2018 | 13.51 Billion |
| 2019 | 12.02 Billion |
| 2020 | 13.62 Billion |
| 2021 | 13.63 Billion |
| 2022 | 17.41 Billion |
| 2023 | 15.37 Billion |
As an investor, you may be considering expanding your portfolio with Merck (USA Stocks: MRK). Merck, a pharmaceutical giant with a market capitalization of
267.14B, offers a yield of 0.0265% and has a book value per share of 18.46X. The company has a solid return on assets of 0.11 and a profit margin of 0.23%, indicating its efficiency in using its assets to generate profit. Merck's total assets amount to
109.16B, and it has a current ratio of 1.46X, suggesting that it can comfortably meet its short-term liabilities. However, the company's risk-adjusted performance stands at -0.06, and it has a standard deviation of 1.12, pointing to a certain level of risk. The company has a healthy EBITDA of 18.62B and a short ratio of 1.99X. Despite a negative income number, the company's net income is framed as a loss of 14.53B. Merck's shares are largely owned by institutions, with 77.43% of its shares held by them. In conclusion, Merck's performance and
financial health make it a viable consideration for portfolio expansion. However, investors should be aware of the associated risks and
make informed decisions.
Merck technical analysis suggests possible turnaround
Merck & Co., Inc. (MRK) has recently exhibited signs of a potential turnaround according to its
technical analysis. Although the potential upside is currently down to 1.63, this could signify a consolidation phase preceding a significant upward movement. Investors are advised to closely monitor the stock's performance and market indicators for any indications of a bullish reversal. This could represent a valuable opportunity for those aiming to capitalize on Merck's potential resurgence. Merck & Co., Inc. displays very low volatility, with a skewness of 0.04 and a kurtosis of -0.47. However, investors are encouraged to further investigate Merck's technical indicators to ensure all market information is accessible and reliable. Understanding various
market volatility trends can often assist investors in timing the market. Proper utilization of volatility indicators allows traders to gauge Merck's stock risk against market volatility during both bullish and bearish trends.
The heightened level of volatility that accompanies bear markets can directly affect
Merck's stock price, adding stress for investors as they watch the value of their shares decline. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In conclusion, Merck (USA Stocks: MRK) presents a compelling investment opportunity despite the modest market slide. The company's stock has been surging slowly, underpinned by a strong
analyst consensus of 'Buy' with
13 strong buys out of
18 estimates. The valuation real value stands at $105.03, slightly below the market value of $105.7, indicating potential for growth. The possible upside price is projected at $109.86, offering a promising return on investment. However, investors should also consider the possible downside price of $107.59. The analyst target price estimated value is an impressive $124.444, with the highest estimated target price reaching as high as $135. Therefore, Merck offers a promising investment opportunity for those looking for steady growth in a turbulent market. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Merck Company. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
